PHARMACY POLICY STATEMENT
Marketplace

DRUG NAME	Mulpleta (lusutrombopag)
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Mulpleta, approved by the FDA in 2018, is a small molecule thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. The agonistic effect upregulates the production of platelets. Mulpleta should not be administered in an attempt to normalize platelet counts. TPO receptor agonists have been associated with thrombotic and thromboembolic complications. Approval of Mulpleta was based on the placebo-controlled L-PLUS 1 and L-PLUS 2 clinical trials. Doptelet is another TPO receptor agonist (TPO-RA) with the same indication as Mulpleta. TPO is important for regulating thrombopoiesis.

Thrombocytopenia is a condition of low platelet counts. It is the most common hematologic complication in patients with CLD, and 1% experience severe thrombocytopenia (platelet count <50,000/µL). Advanced disease often requires numerous medical and/or surgical diagnostic and therapeutic procedures. Thrombocytopenia may be associated with increased bleeding risk in these invasive procedures. Mulpleta has been shown to reduce the need f3. Q q 0.00000919a.

CareSource considers Mulpleta (lusutrombopag) not medically necessary for the treatment of conditions that are not listed in this document. For any other